Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Table 2 Surgical sample PDX by clinical molecular subtype

Clinical molecular subtype	Total implanted	Any tumor growth	Verified breast tumor (%)
ER-/HER2+	3	1	1 (33.3)
ER+/HER2+	5	0	0 (0.0)
LumA	3	0	0 (0.0)
LumB	18	2	0 (0.0)
LumUnk	1	0	0 (0.0)
Triple negative	9	4^b	5 (55.6)
Totals	35^a	7	6 (17.1)

Abbreviations: PDX patient-derived xenograft, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, LumA luminal A, LumB luminal B, LumUnk luminal unknown
^aAn additional two tumors were implanted and had growth but were not available for pathological confirmation
^bOne triple negative PDX did not grow to the defined growth threshold due to mouse health condition, but did passage with verification

ISSN: 1465-542X